Salmeterol Xinafoate: EP

At PLS, we believe that success is defined by the positive impact which we make on the world around us. Since the beginning, our goal has always been to provide access to affordable healthcare solutions to millions of people who are in need.
We are a lean company with skilled,educated & experienced professionals who look after various critical operations on day to day basis and have been successfully able to establish the base for a bigger business platform globally. Our present core focus area remains APIs and intermediates Salmeterol Xinafoate: EP.
Over a period of time PLS has successfully been able to develop new products, gained market approvals, made commercial supplies to customers of reupte in both domestic and international markets & have created a basket which will bring in growh for the company and its people. Our Products are being exported to LATAM, Middle East and Asian subcontinents.
We plan to venture into formulation and finished dosage business and are open for new ideas for collaborations & believe in co-creation of breakthrough solutions Salmeterol Xinafoate: EP.
Progress curently holds Good manufacturing practices (GMP) license issued by food and drug administration Pune – in accredition to the practices being followed to manufacture the goods therein.
Inhaled salmeterol belongs to a group of drugs called beta-2 agonists. These drugs stimulate beta-2 receptors present in the bronchial musculature. This causes them to relax and prevent the onset and worsening of symptoms of asthma. They act on the enzyme adenyl cyclase which increases the concentration of cAMP (Cyclic adenosine monophosphate). This cyclic AMP decreases the smooth muscle tone. This drug is 10,000-times more lipid soluble than the short acting beta-2 adrenoceptor agonist, albuterol. Unlike albuterol, salmeterol becomes dissolved in the lipid bilayer of the cell membrane, and its gradual dissociation from the cell membrane provides beta-2 adrenoceptors with a supply of agonist for an extended period of time.